Boston University Announces Launch of SEQSTER's 1-Click Records™ to Aid in Development of Early Alzheimer's Screening Tool
29 July 2024 - 11:03AM
Business Wire
The system will allow researchers to retrieve a
person’s longitudinal health record in seconds.
DxA-Funded Researcher and Goodes Prize Winner
Dr. Rhoda Au will leverage data to develop AI-powered
risk-assessment tool.
SEQSTER PDM Inc. ("SEQSTER"), the leading patient-centric
healthcare technology company, announces at the Alzheimer's
Association International Conference 2024 in Philadelphia,
Pennsylvania it will work with Boston University researchers led by
Rhoda Au, PhD, Professor of Anatomy and Neurobiology at Boston
University Chobanian & Avedisian School of Medicine,
Diagnostics Accelerator (DxA)-funded investigator, and recipient of
the Alzheimer’s Drug Discovery Foundation’s (ADDF) 2023 Melvin R.
Goodes Prize for Excellence in Alzheimer's Drug Development. The
project, funded by the Goodes Prize, will leverage SEQSTER’s
1-Click Records to collect health information, providing the
longitudinal data needed for Dr. Au and her team to begin
developing an early-stage clinical screening tool for
Alzheimer’s.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240729113746/en/
SEQSTER's 1-Click Records™ to Aid in
Development of Early Alzheimer's Screening Tool (Graphic: Business
Wire)
“Early intervention is crucial in managing Alzheimer's, and this
project holds promise in identifying individuals at the earliest
stages. We chose to use SEQSTER's 1-Click Records because of its
instant data connectivity with electronic health records,” states
Dr. Au. “As a long-time investigator of the 75-year-old Framingham
Heart Study, I view this tool as a way to create a Framingham-like
study by aggregating all of a patient’s longitudinal health data.
More importantly, SEQSTER empowers participants to decide what
medical information they want to contribute, keeping the control of
their medical data, while also helping accelerate scientific
progress.”
SEQSTER's 1-Click Records offers a way to streamline and
simplify data collection from multiple sources, unifying a
patient’s electronic health record (EHR) data. The interface allows
participants to opt in to contributing their data, promoting wider
participation in the study and accelerating research.
Dr. Au and her team will leverage SEQSTER's 1-Click Records to
combine participants’ current and previous health data and will
link it to blood based biomarkers and digital cognitive assessments
they will be conducting. Dr. Au hopes that the breadth of this data
will help her develop an AI-powered screening tool that can
identify whether patients are at a higher risk for Alzheimer’s or
are even subtly symptomatic.
“We know that Alzheimer’s pathology appears at least 20 years
before symptoms present, and we don’t yet have the biomarkers or
diagnostic tools to identify these changes in real-time,” says
Howard Fillit, MD, Co-Founder and Chief Science Officer of the
ADDF. “Dr. Au is a pioneer in the development of digital biomarkers
and screening tools, and we hope her research will enable early
diagnosis and intervention for Alzheimer’s, which researchers
believe could have a profound impact on the progression of the
disease.”
In 2015, Former Warner-Lambert CEO and Chairman, Melvin R.
Goodes, and his family established The Melvin R. Goodes Prize for
Excellence in Alzheimer’s Drug Discovery alongside the ADDF. The
award offers a $150,000 grant to support the winner’s future
research. Dr. Rhoda Au was selected as the Goodes Prize Honoree in
2023, and this project is being funded with her prize money.
“This collaboration is another demonstration of our commitment
to impact Alzheimer’s Disease while supporting individuals and
their caregivers,” adds Ardy Arianpour, CEO & Co-Founder of
SEQSTER. “As people may know, this is very personal for me as
Alzheimer’s Disease struck both my maternal and paternal
grandmothers and I will stop at nothing to fight to find a cure. By
combining SEQSTER's 1-Click Records with Boston University's
innovative research approach, I envision a future where this
collaboration transforms the landscape of Alzheimer's screening,
providing individuals and families with an accessible and efficient
tool for early detection.”
About The Alzheimer’s Drug Discovery Foundation
(ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the
Alzheimer's Drug Discovery Foundation is dedicated to rapidly
accelerating the discovery of drugs to prevent, treat and cure
Alzheimer's disease. The ADDF is the only public charity solely
focused on funding the development of drugs for Alzheimer's,
employing a venture philanthropy model to support research in
academia and the biotech industry. The ADDF's leadership and
contributions to the field have played a pivotal role in bringing
the first Alzheimer's PET scan (Amyvid®) and blood test
(PrecivityAD®) to market, as well as fueling the current robust and
diverse drug pipeline. Through the generosity of its donors, the
ADDF has awarded more than $290 million to fund over 750
Alzheimer's drug discovery programs, biomarker programs and
clinical trials in 20 countries. To learn more, please visit:
http://www.alzdiscovery.org/.
ABOUT Boston University
Founded in 1839, Boston University is an internationally
recognized institution of higher education and research. With
nearly 37,000 students, it is one of the largest private
residential universities in the United States. BU consists of 17
schools and colleges, along with the Faculty of Computing &
Data Sciences and a number of multi-disciplinary centers and
institutes integral to the University's research and teaching
mission. In 2012, BU joined the Association of American
Universities (AAU), a consortium of leading research universities
in the United States and Canada.
ABOUT SEQSTER
SEQSTER is the leading healthcare technology company that breaks
down health data silos at scale. Its enterprise operating system
aggregates disparate health data sources into a single, 360-degree
view of a patient in real-time, solving a multitude of challenges
for life sciences, patient engagement and data
interoperability.
SEQSTER has nationwide coverage of EHRs from hospitals and
medical groups, genomic DNA, wearables, pharmacy and social
determinants of health data. Through its customizable white-label
approach, SEQSTER provides accelerated access to de-identified,
tokenized, real-time data and comprehensive curated data to address
critical needs across the healthcare continuum.
SEQSTER is privately held and headquartered in San Diego.
To learn more about SEQSTER, please contact us at
info@seqster.com or visit www.seqster.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729113746/en/
Media Contacts Gina DiGravio (617) 358-7838 ginad@bu.edu Bill
Douglass SEQSTER press@seqster.com